IL17A and glomerulonephritis: The previous studies on the IL‐17 signalling pathway have indicated that metabolic inflammation‐associated IL‐17A leads to MASH53 and that the IL‐17 signalling pathways are a potential therapeutic target for rapidly progressive glomerulonephritis.54